Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands

Breast Journal

Volumn 19, Issue 4, 2013, Pages 394-401

  Van Herk Sukel, Myrthe P P ^a   Van De Poll Franse, Lonneke V ^b,c   Creemers, Geert Jan ^d   Lemmens, Valery E P P ^b,e   Van Der Linden, Paul D ^f   Herings, Ron M C ^a,e   Coebergh, Jan Willem W ^b,e   Voogd, Adri C ^b,g  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f TERGOOI HOSPITAL   (Netherlands)

^g MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

anthracyclines; breast cancer; chemotherapy regimen; population based; taxanes; trastuzumab; trend

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER STAGING; FEMALE; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PRACTICE GUIDELINE;

ANTHRACYCLINES; BREAST CANCER; CHEMOTHERAPY REGIMEN; POPULATION BASED; TAXANES; TRASTUZUMAB; TREND;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; NETHERLANDS; PALLIATIVE CARE; RECEPTOR, ERBB-2; REGISTRIES; TAXOIDS;

EID: 84879785974     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12125     Document Type: Article

References (28)

1. Moulder S, Hortobagyi GN,. Advances in the treatment of breast cancer. Clin Pharmacol Ther 2008; 83: 26-36.
2. Lopez-Tarruella S, Martin M,. Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res 2009; 11: 204.
3. Buzdar AU,. Preoperative chemotherapy treatment of breast cancer-a review. Cancer 2007; 110: 2394-407.
4. Tkaczuk KH,. Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin Ther 2009; 31 (Pt 2): 2273-89.
5. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C,. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332: 901-6.
6. Barrett-Lee PJ, Dixon JM, Farrell C, et al,. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 2009; 20: 816-27.
7. Piccart MJ, de Valeriola D, Dal Lago L, et al,. Adjuvant chemotherapy in 2005: standards and beyond. Breast 2005; 14: 439-45.
8. Ring AE, Ellis PA,. Taxanes in the treatment of early breast cancer. Cancer Treat Rev 2005; 31: 618-27.
9. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV,. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007; 7: 153.
10. Guideline 'Treatment of breast cancer' Utrecht, the Netherlands Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2005.
11. Guideline 'Treatment of breast cancer' Utrecht, the Netherlands Kwaliteitsinstituut voor de Gezondheidszorg CBO, 2002.
12. Rutgers EJ, Nortier JW, Tuut MK, et al,. [ Dutch Institute for Healthcare Improvement guideline, 'Treatment of breast cancer' ]. Ned Tijdschr Geneeskd 2002; 146: 2144-51. CBO-richtlijn 'Behandeling van het mammacarcinoom'.
13. Harlan LC, Abrams J, Warren JL, Clegg L, Stevens J, Ballard-Barbash R,. Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol 2002; 20: 1809-17.
14. Shen Y, Dong W, Feig BW, Ravdin P, Theriault RL, Giordano SH,. Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer. 2009; 115: 2041-51.
15. Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS,. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24: 2750-6.
16. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al,. New opportunities for drug outcomes research in cancer patients: The linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 2010; 46: 395-404.
17. ®) for the indication of first line treatment of metastastatic breast cancer". The Netherlands: Dutch "Commissie Farmaceutische Hulp" (Committee for Pharmaceutical Help; CFH). 2007 22 October 2007. Report No.
18. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
19. Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D,. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol 2004; 5: 372-80.
20. Romond EH, Perez EA, Bryant J, et al,. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al,. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
22. Dicato M,. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist 2008; 13 (Suppl 3): 11-5.
23. Du X, Goodwin JS,. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 2001; 19: 1455-61.
24. Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R,. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 2006; 24: 872-7.
25. Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J,. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 2002; 94: 1626-34.
26. Sukel MP, van de Poll-Franse LV, Nieuwenhuijzen GA, et al,. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer 2008; 44: 1846-54.
27. Suter TM, Procter M, van Veldhuisen DJ, et al,. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.
28. Bonneterre J, Spielman M, Guastalla JP, et al,. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 1999; 35: 1431-9.